Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Galapagos announces full year 2023 results and outlook for 2024
23 Feb 24
6-K
Galapagos presents at EBMT-EHA annual meeting 2024
16 Feb 24
6-K
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6 Feb 24
6-K
Current report (foreign)
4 Jan 24
6-K
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4 Jan 24
6-K
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4 Jan 24
6-K
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
21 Dec 23
6-K
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
12 Dec 23
6-K
Current report (foreign)
12 Dec 23
S-8
Registration of securities for employees
4 Dec 23
6-K
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
3 Nov 23
6-K
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
2 Nov 23
6-K
Galapagos appoints Simon Sturge to its Board of Directors
20 Sep 23
6-K
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
30 Aug 23
6-K
Galapagos announces first half-year 2023 financial results
4 Aug 23
6-K
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
15 Jun 23
6-K
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
13 Jun 23
6-K
Current report (foreign)
12 Jun 23
6-K
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
25 May 23
6-K
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
23 May 23
6-K
Galapagos creates new subscription right plans
9 May 23
6-K
Galapagos announces first quarter 2023 financial results
5 May 23
6-K
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
2 May 23
6-K
Current report (foreign)
2 May 23
6-K
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
26 Apr 23
6-K
Current report (foreign)
25 Apr 23
6-K
Current report (foreign)
31 Mar 23
6-K
Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting
27 Mar 23
20-F
2022 FY
Annual report (foreign)
23 Mar 23
6-K
Current report (foreign)
23 Mar 23
6-K
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
28 Feb 23
6-K
Galapagos announces full year 2022 results and outlook for 2023
24 Feb 23
6-K
Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL
10 Feb 23
6-K
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
8 Feb 23
6-K
Current report (foreign)
19 Jan 23
6-K
Galapagos receives transparency notification from FMR LLC
10 Jan 23
6-K
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
5 Jan 23
6-K
Galapagos receives transparency notification from FMR LLC
5 Jan 23
6-K
Galapagos announces changes to Executive Committee
23 Dec 22
Latest ownership filings
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
EcoR1 Capital, LLC
7 Jun 23
SC 13G/A
EcoR1 Capital, LLC
14 Feb 23
SC 13G
FMR LLC
9 Feb 23
SC 13G
EcoR1 Capital, LLC
3 Feb 22
SC 13D
VAN HERK INVESTMENTS B.V.
2 Nov 21
SC 13G/A
Capital International Investors
10 May 21
SC 13G/A
Capital International Investors
10 Feb 21
SC 13G
Capital International Investors
10 Feb 21
SC 13G/A
VAN HERK INVESTMENTS B.V.
29 Jan 21
SC 13G/A
Galapagos NV
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Galapagos NV
27 Jan 20
SC 13D/A
Galapagos NV
1 Nov 19
SC 13D/A
Galapagos NV
29 Aug 19
SC 13D
Galapagos NV
23 Jul 19
SC 13G/A
Galapagos NV
17 Jul 19
SC 13G/A
Galapagos NV
14 Feb 19
SC 13G
Galapagos NV
12 Feb 19
SC 13G
Galapagos NV
10 Jan 19
SC 13G/A
Galapagos NV
23 Nov 18
SC 13G/A
Galapagos NV
12 Jun 18
SC 13G/A
Galapagos NV
8 Mar 18
SC 13G/A
Galapagos NV
16 Feb 18
SC 13G/A
Galapagos NV
15 Feb 17
SC 13G/A
Galapagos NV
9 Feb 17
SC 13G/A
Galapagos NV
10 Aug 16
SC 13G/A
Galapagos NV
16 Feb 16
SC 13G
Galapagos NV
11 Feb 16
SC 13G
Galapagos NV
11 Feb 16
SC 13G
Galapagos NV
27 Jan 16
SC 13G
Galapagos NV
18 Jun 15